



PATENT
Docket No.: LAY-011 CIA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 2632

Examiner: N/A

Serial No.: 09/882,934

Filed: June 15, 2001

In re Application of: Shytle et al.

For: EXO-R-MECAMYLAMINE FORMULATION AND USE IN TREATMENT

RECEIVED

JAN 10 2002

Technology Center 2600

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Director of Patents, Washington, D.C. 20231 on 11/27/01, Signed T. Bounds

Tina Bounds

INFORMATION DISCLOSURE STATEMENT

Director of Patents
Washington, D.C. 20231

Dear Sir:

Each item of information listed in the attached FORM PTO-1449, for which a copy of each is attached, may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR §§1.56, 1.97 and 1.98. The Examiner is requested to make these items of official record in this application.

This Information Disclosure Statement under 37 CFR §§1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

I

This statement is filed pursuant to:

(x) 37 C.F.R. §1.97(b).

This information disclosure statement is filed either (1) within three months of the filing date of the national applications; (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or (3) before the mailing date of a first office action on the merits, whichever event occurs last.

Accordingly, this information disclosure statement requires no fee and no certification.

() 37 C.F.R. §1.97(c).

This information disclosure statement is filed after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of either (1) a final action under 37 C.F.R. §1.113 or (2) a notice of allowance under 37 C.F.R. §1.311.

Accordingly, this information disclosure statement requires either the fee specified in 37 C.F.R. § 1.17 (p) for submission of an information disclosure statement under 37 C.F.R. §1.97(c) (\$240), or a certification according to 37 C.F.R. §1.97(e).

() 37 C.F.R. §1.97(d).

This information disclosure statement is filed after the period specified in 37 C.F.R. §1.97(c).

Accordingly, this information disclosure statement requires the petition fee specified in 37 C.F.R. §1.17(i) (1) to consider an information disclosure statement under 37 C.F.R. § 1.97(d) (\$130), a certification according to 37 C.F.R. §1.97(e), and a petition requesting consideration of the information disclosure statement.

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. §1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

II

(X) No fee is due

() The fee specified in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under 37 C.F.R. §1.97(c) is enclosed (\$240).

() The petition fee specified in 37 C.F.R. § 1.17(i) (1) to consider an information disclosure statement under 37 C.F.R. § 1.97(d) is enclosed (\$130.00).


Please charge any additional required fee or credit any overpayment to our deposit account number 50-0612.

III

Pursuant to 37 C.F.R. §1.97(e), I certify:

- (X) No certification is necessary.
- () (1) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.
- () (2) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c), more than three months prior to the filing of the statement.

Respectfully submitted,
SIERRA PATENT GROUP, LTD.



Barbara J. Luther
Reg. No.: 33,954

Dated: November 27, 2001

Sierra Patent Group, Ltd.
P.O. Box 6149
Stateline, NV 89449
(775) 586-9500



RECEIVED

JAN 10 2002

Page 2 of 2

Form PTO 1449 (Rev. 2-32)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. LAY-011 CIA		Serial No. 09/882,934	
Information Disclosure Statement by Applicant				Applicant: Shytle et al.			
(Use several sheets if necessary)				Filed: June 15, 2001		Group: 2632	
Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)							
	4	Papke, Roger L., et al., "Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes", The American Society for Pharmacology and Experimental Therapeutics, The Journal of Pharmacology and Experimental Therapeutics, Vol. 297, No. 2, 2001, pp. 646-656.					
	5	Suchocki, John A., et al., "Synthesis of 2-exo- and 2-endo-Mecamylamine Analogues. Structure-Activity Relationship for Nicotinic Antagonism in the Central Nervous System", American Chemical Society, J. Med. Chem., 34, 1991, pp.1003-1010.					
	6	Hennings, Esteban C.P., et al., "Nicotinic Acetylcholine Receptor Antagonistic Activity of Monoamine Uptake Blockers in Rat Hippocampal Slices", International Society for Neurochemistry, Journal of Neurochemistry 73, 1999, pp. 1043-1050.					
	7	Gardiner, Mark R., "Genetic Basis of the Human Epilepsies", Elsevier Science B.V., Epilepsy Research, Vol. 36, 1999, pp. 91-95.					
	8	Schonenberger, Bernhard, et al., "Preparation of Optically Active Secondary Amines by Thermal Decomposition of (Methylbenzyl)urea Analogs: Absolute Configuration of (+) and (-) Mecamylamine", Helvetica Chimica Acta - Vol. 69, 1986, pp.283-287.					
	9	Martin, Thomas J., et al., "Pharmacological Evaluation of the Antagonism of Nicotine's Central Effects by Mecamylamine and Pempidine", The American Society for Pharmacology and Experimental Therapeutics, The Journal of Pharmacology and Experimental Therapeutics, Vol. 254, No. 1, 1990, pp. 45-51.					
	10	Stone, Clement A., et al., "Chemistry and Structure-Activity Relationships of Mecamylamine and Derivatives", The American Chemical Society, Journal of Medicinal and Pharmaceutical Chemistry, Vol. 5, No. 4, 1962, pp. 665-690.					
	11	Goodman, Elizabeth, et al., "Depressive Symptoms and Cigarette Smoking Among Teens", The American Academy of Pediatrics, Pediatrics Vol. 106, No. 4, October 2000, pp. 748-755.					
	12	Tattersall, F.D., et al., "Enantiospecific Inhibition of Emesis Induced by Nicotine in the House Musk Shrew (Suncus murinus) by the Neurokinin ₁ (NK ₁) Receptor Antagonist CP-99,994", Elsevier Science, Ltd., Neuropharmacology, Vol. 34, No. 12, 1995, pp. 1697-1699.					
Examiner				Date Considered			
Examiner: Initial if citation considered, whether or not citation is in conference with MPEP 609; Draw line through citation if not conformance and not considered. Include a copy of this form with the next communication to applicant.							